Supply & Shortage
See below for general resources related to vaccine supply. In the case of disrupted supply, the following resources can keep you informed, and provide information to help keep your patients up to date.
Current Pediatric Vaccine Shortage
Pediatric hepatitis B vaccine Recombivax HB will be in short supply through the middle of Quarter Two of 2019. In a letter to providers in 2017, Merck said demand around the world and manufacturing process updates caused the shortage of Recombivax HB in both pediatric and adult formulations. This shortage impacts the following package sizes for the pediatric/adolescent formulation: ten (10) 5 mcg/0.5 mL single-dose pre-filled Luer-Lok® syringes with tip caps and 5mcg/0.5mL - 10 single-dose 0.5mL vials. More information can be found on the Merck Supply Status page.
There is no change in the recommendations for hepatitis B vaccine administration – 3 dose series (birth, 1-2 months of age and 6-18 months of age). During this shortage, the Center for Disease Control and Prevention (CDC) recommends prioritizing the birth dose and completion of the infant series over child and adolescent catch-up vaccination unless those patients are at a risk for infection. For more information about hepatitis B and current hepatitis B vaccination recommendations, see the AAP Vaccine Preventable Diseases and Policy page.
GlaxoSmithKline (GSK) has an adequate supply of hepatitis B vaccine to make up for the shortage, according to the CDC. GSK produces single-component Engerix-B and the combination vaccine Pediarix. For more information regarding ordering supply from GSK, visit the GSK Direct Website or reference the GSK Direct Customer Resource Guide.
CDC clinical guidance during this supply shortage is available here.
AAP announces the hepatitis B shortage to members via AAP News, Merck HepB vaccine shortage extended; GSK has supply.